Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Klotho beta (KLB) is a single-pass transmembrane protein that functions as an obligatory co-receptor for the endocrine fibroblast growth factors FGF19 and FGF21. It plays a critical role in regulating bile acid synthesis, glucose homeostasis, lipid metabolism, and energy expenditure. KLB primarily acts by forming complexes with FGFRs upon binding with FGF19 or FGF21, triggering downstream signaling cascades. Its involvement in metabolic regulation makes it a potential therapeutic target, with mimetics of its ligands showing promise in clinical trials.
KLB acts as an essential co-receptor for certain endocrine fibroblast growth factors, notably FGF19 and FGF21, facilitating their binding to FGFRs and subsequent downstream signaling involved in metabolic regulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Klotho Beta (KLB).